retatrutide clinical trial duration Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide Dosing Guide: 1-12 mg

In alzheimers disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial

GLP-1 drugs target the GLP-1 trans-membrane receptor, which is one of a large family of G protein-coupled receptor (GPCR) proteins that straddle cell membranes and transduce chemical signals from outside the cell to its interior

Butler, P

doi: 10.1016/j.ahj.2018.03.030

There are multiple drug names and mechanisms, ongoing debates about who should take the drugs, questions about cost and access, and anxiety about what happens if you stop taking them

Use these insights to craft targeted messaging and conversion strategies that guide patients toward branded therapies